White SARMS Raw Powder Selective Androgen Receptor Modulator Gw-501 / 516
Contact Person : Qin
Phone Number : +86 13663845045
WhatsApp : +8613663845045
|Minimum Order Quantity :||10g||Price :||Negotiable|
|Packaging Details :||White Box or parcel packing||Delivery Time :||within 5hours|
|Payment Terms :||T/T, Western Union, MoneyGram, Bitcoin||Supply Ability :||100kg/Month|
|Place of Origin:||China||Brand Name:||Filter|
|Name:||Supply SARMS RawPowder LGD-4033 / Ligandrol Weight Loss||Another:||Ibutamoren|
|Shief Life:||2 Years||Color:||White|
arms anabolic steroids,
sarms bodybuilding supplements
LGD-4033 Ligandrol SARMS Raw Powder Weight Loss And Muscle Building
What Actually Is Ligandrol?
LGD-4033 is a non-steroidal selective androgen receptor modulator (SARM).
An androgen (from Greek ‘andro’ meaning male human being) is a compound (natural or synthetic) that regulates the development and maintenance of male characteristics in vertebrates (including humans) by binding to androgen receptors (special receptors on cells). Androgens are often steroid hormones.
A selective androgen receptor modulator (SARM) is selective in its target tissues in the body. That means it has a high affinity to bind with androgen receptors. Being “selective”, SARMS can be taken by mouth but only binds to specific target areas- in this case – to androgen receptors in your muscles.
There are many conditions that result in muscle wastage. As we age, we lose lean muscle mass and muscle strength, which is called “Sarcopenia”. Sarcopenia is known to increase the risk of falls, fractures, physical disability, and result in poor quality of life with significant health and economic effects.
Similarly, many illnesses, such as chronic obstructive lung disease, muscular dystrophy, end-stage renal disease, and some types of cancer, is punctuated by the loss of lean muscle mass and physical function, which contributes to mobility limitation and disability , .
Thus, there is a need for anabolic therapies that combat lean tissue loss and physical function and reduce the burden of disability in persons experiencing it due to aging or illness . Among the various candidate anabolic therapies that are in development, androgens are the farthest along in development .
It is widely recognized that testosterone administration increases muscle mass and strength but concerns regarding its potential adverse effects have motivated efforts to develop SARMs, a new class of androgen receptor ligands that are tissue-selective . SARMs modulate the same anabolic pathways targeted with classical steroidal androgens8.
The last decade has witnessed substantial pharmaceutical efforts to develop nonsteroidal SARMs to treat muscle wasting and functional limitations associated with acute and chronic illness and aging.
This class of SARMs has been the subject of much clinical research over the past two decades8. LGD-4033 binds androgen receptors with high affinity and selectivity, ie it binds in a strong and targeted manner . It is expected to produce the therapeutic benefits of testosterone with improved safety, tolerability, and patient acceptance.
There has been a lot of research into the efficacy of SARMs but very little published research to date on LGD.
LGD-4033 has exhibited desirable in vivo effects on skeletal muscle and bone measurements in animal models of disease. There is only one published study on the effects of LGD in humans as well as Phase I Clinical Trial results.
A 2010 Phase I clinical trial was the first study in humans of LGD-4033, and evaluated the safety, tolerability and pharmacokinetic effects (how it acts in the body) of the molecule in a single escalating dose, double-blind, placebo-controlled study in 48 healthy volunteers.
In 2013, Basaria conducted a rigorous 3-week placebo-controlled study of 76 healthy men (21–50 years) that looked at the safety and tolerability of LGD-4033. It hopefully paves the way for longer-term efficacy trials in one or more populations of older individuals for which SARMs may be indicated .
During this study, participants were randomized to placebo or 0.1, 0.3, or 1.0 mg doses of LGD-4033 daily for 21 days. The study evaluated the safety, tolerability, pharmacokinetics (how it works in the body), and effects of ascending doses of LGD-4033 administered daily for 21 days on lean body mass, muscle strength, stair-climbing power, and sex hormones .
Despite being a well designed, thorough study, the sample size, although substantially larger than in most phase I ascending-dose studies, was still fairly small, was not based on considerations of effect sizes , as the study’s primary aim was to establish safety and tolerability rather than efficacy. Similarly, the 3-week study duration was not designed to demonstrate maximal effects on muscle mass and strength . Therefore larger and longer studies are needed to assess the efficacy of LGD.
One further thing to note is that the study was supported by Ligand Pharmaceuticals, who developed LGD, so it’s impossible to say that the research was completely impartial.
No. Research by Basiria showed a dose-dependent suppression of total testosterone and from baseline to day 21 , rather than an increase.
No. The research does not show that LGD promotes fat loss
Does Ligandrol Promote Muscle Growth?
Yes. But it’s very early, weak evidence at this stage. The research by Basiria showed an increase in lean body mass that was dose related, so as the dose of LGD taken increased, so did the effect of increased muscle mass .
The mechanisms by which androgens increase muscle mass remain incompletely understood . It would be plausible that increased muscle mass would translate into increased muscle strength.
Research has shown that SARMs increase muscle mass and improve physical function in healthy and diseased individuals and potentially may provide a new therapy for muscle wasting, especially in the case of cancer8.
However, the increase in strength measured by stair climbing speed and power also showed improvement, but not enough to be statistically significant. With a larger sample size and or a longer study, it is possible that this effect may be demonstrated.
You probably shouldn’t be, as there is not enough research yet. But no adverse effects have been noted at this stage.
LGD-4033 displayed an immediate effect on hormones in the body from the time it was taken. In terms of functionality, the research showed gains in lean muscle mass within the 21-day study, which is a pretty amazing result for a short space of time .
LGD-4033 displayed a prolonged elimination half-life, which means the time it takes for half of the dose to leave your system, of 24–36 hours. That is every 24-36 hours, the level of LGD in your system drops by half . The following day, the level drops by half again, and so forth.
Upon discontinuation of LGD-4033, the hormone levels returned to baseline by day 56 .
Both the Phase I Trial and study by Basiria showed that LGD-4033 was safe and well-tolerated at all doses administered (0.1mg, 0.3mg, and 1.0mg). The frequency of adverse events was similar between the placebo and any dose group. Headache, pain related to muscle biopsy, and dry mouth were the most common events and did not show dose relationship.
One of the clinically useful features of LGD is its half life. Its prolonged elimination half-life means that is can be given once daily or even a less frequent dosing regimen. Research showed that there was a robust relationship between the dose and the blood plasma concentrations.
The past decade has witnessed the emergence of a number of nonsteroidal SARMs from several pharmaceutical companies as a new class of function-promoting therapies to treat the loss of muscle mass.
Recent clinical efficacy data for LGD-4033 is very promising, showing it to be safe and able to increase lean body mass even during a three week period, which is a fantastic result in a short time. But it must be remembered that this was recorded in a single study with a small sample size (76 people), and the Phase I Clinical trial also had a small sample size (48 people).
There just is not enough research to show its efficacy at this stage, despite it looking super promising!
Although future research may show LGD to be safe and efficacious, the evidence is just not strong enough to support it right now. Given the global burden of diseases that involve muscle wastage, including aging, cancer, and osteoporosis, it is very likely that further research and trials will come out with stronger evidence for its clinical usage.
1.COA HPLC MS be sent on request
Enter Your Message